Doxycycline in Type II Diabetes
Recruiting · NCT06329882 · Interventional (participants receive a specific treatment) · Lead sponsor: Mostafa Bahaa
View the official record on ClinicalTrials.gov →Interventions studied
DoxycyclinSitagliptin 100mg
What this trial is about
Type 2 diabetes mellitus (T2DM) is a chronic metabolic disease characterized by hyperglycemia, weight loss, and cardio-metabolic complications. T2DM develops due to the progression of insulin resistance (IR), impairment of insulin insensitivity, and failure of the pancreatic β-cells to release sufficient amount of insulin in response to glucose burden
Who can take part
Age range
40 Years to 60 Years
Sex
All (male and female)
Healthy volunteers
No - a diagnosis or condition is required
Phase
Phase 1, Phase 2
Study type
Interventional (participants receive a specific treatment)
Inclusion criteria
- Male or female sex more than 40 years old Newly diagnosed type II diabetes. HbA1c more than 6.5
Exclusion criteria
- Patient with chronic kidney disease, hepatic disorders, mental and psychiatric disorders, pregnancy, and lactation
Where it is running
1 location listed.
- Tanta Unuversity - Tanta, Egypt